Customized Chemotherapy Did Not Improve Survival in Early NSCLC Customized Chemotherapy Did Not Improve Survival in Early NSCLC

Tailoring adjuvant chemotherapy based on the expression of two molecular markers did not confer a survival advantage in patients with completely resected stage 2-3 NSCLC in a phase 3 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news